Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Gastric Cancer
NCT04694183Phase 2Completed
- Start
- Aug 2020
- Primary completion
- May 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in gastric cancer (GC). Primary endpoint: R0 resection rate at 1 month. Started Aug 2020; status: completed.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04694183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04694183.